Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Silverback Therapeutics, Inc. (SBTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.43+0.15 (+2.84%)
At close: 04:00PM EDT
5.43 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment

    ARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ: SBTX) in an all-stock transaction, with a new entity operating under the ARS Pharmaceuticals name and trade on NASDAQ under the SPRY symbol. The combined company will focus on neffy, ARS's investigational epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. The combined entity is expected to have approximately $265 million in cash and equivalents at closing. Also Read: Silverback Therapeutics Ax

  • Business Wire

    Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

    SEATTLE & SAN DIEGO, July 21, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. T

  • Simply Wall St.

    What You Need To Know About Silverback Therapeutics, Inc.'s (NASDAQ:SBTX) Investor Composition

    The big shareholder groups in Silverback Therapeutics, Inc. ( NASDAQ:SBTX ) have power over the company. Large...

Advertisement
Advertisement